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Cancer cells can move through tissues in a variety of different ways. In some cases, an epithelial-to-mesen-
chymal transition enables cancer cells to acquire fibroblast-like migratory properties. However, it is
also becoming apparent that some cancer cells move in an amoeboid way similar to leukocytes. This theme
will be the focus of the review, wherewewill discuss the similarities and differences between themechanisms
used by cancer cells and leukocytes to cross parenchymal basement membranes, move through interstitial
tissue, and enter and exit the vasculature. Further, we propose that the ability to switch between different
migratory mechanisms is critical for cells to relocate from one tissue to another.Introduction
The spread of cancer is a major clinical problem. As cancer cells
disperse through the body, they encounter a diverse range of
extra-cellular matrices (ECMs). These range from basement
membranes (BMs) associated with either parenchymal tissue
or vascular networks to interstitial collagen-rich matrices. These
matrices present a considerable and varied barrier for cells to
cross. Nonetheless, these barriers are routinely traversed
during the course of immune surveillance. Indeed, a functional
immune system depends on the ability of immune cells to traffic
through a range of peripheral and vascular tissues. This traf-
ficking occurs without general loss in tissue architecture. It has
been proposed that cancer cells often acquire the characteris-
tics of mesenchymal cells to cross tissue boundaries. Recent
work has demonstrated that cancer cells can negotiate three-
dimensional matrices in a variety of ways, some of which are
not easily reconciled as mesenchymal cell behavior. In this
review, we will instead explore an alternative possibility that
cancer cells mimic the behavior of immune cells that are inher-
ently adapted for crossing tissue boundaries and moving
through the interstitium. We will discuss how leukocytes and
cancer cells cross epithelial BMs, travel through the interstitium,
and enter and exit the vasculature. Both similarities and differ-
ences will be highlighted together with examples of leukocytes
facilitating cancer cell invasion. We will also argue that the ability
to convert between different strategies of invasion is key to
cancer cell dissemination.
Crossing Parenchymal Basement Membranes
In epithelial cancers, the first BM to be compromised is the
parenchymal BM underlying the tissue in which the cancer
arises. This BM is also routinely traversed by immune cells scan-
ning for signs of infection. For example, Langerhans cells (LCs)
reside in the epidermis and move into the dermis upon detection
of an immunological threat, and both T cells and antibody-
producing B cells cross the intestinal BM into the gut to fight
infection. Parenchymal BMs are typically 50–100 nm thick and
composed of a diverse assembly of macromolecules (Kalluri,
2003). The main constituents are type IV collagens, laminins,
nidogen, and heparin sulphated proteoglycans such as perle-
can. Many of these components can be cross-linked to enhance
the stability and barrier function of the BM. Pores in parenchymalBMs are small (50 nm), and therefore cells are believed to
remodel the BM as they move through (Abrams et al., 2000a;
Abrams et al., 2000b; Kuntz and Saltzman, 1997; Tucker et al.,
1992).
The Adhere, Degrade, and Move Paradigm
The bulk of our mechanistic understanding of how BMs are
traversed is based on in vitro systems. Much of this literature
uses the ‘‘Transwell’’ assay, which involves a reconstituted BM
layer covering a filter with holes of defined dimensions (3–8 mm).
These types of studies together with in vivo data have led to the
following general model of how both leukocytes and cancer cells
cross BMs (Figure 1A). First, integrin-mediated adhesion to the
matrix is required (Guo and Giancotti, 2004). Subsequently,
proteases degrade the BM before actin polymerization extends
cell protrusions through the hole (Madri and Graesser, 2000;
Rowe and Weiss, 2008; Yamaguchi et al., 2005b). Finally, the
cell body moves behind the actin-rich protrusion (Olson and
Sahai, 2009). While this general scheme is widely accepted,
there are conflicting reports on which integrins and proteases
are key for crossing BMs.
Attempts to resolve the contrasting results from in vitro studies
using either genetic ablation or chemical inhibitors in mouse
models have not provided simple answers (protease literature
reviewed in Overall and Lopez-Otin, 2002). Defects in leukocyte
penetration of the BMs might be expected to result in immune
disorders. Thus, the mouse model of experimental autoimmune
encephalomyelitis (EAE) is a useful in vivo model to examine
leukocyte penetration of BMs. After extravasation of the brain
endothelium, leukocytes first penetrate the endothelial BM and
subsequently traverse the parenchymal BM. In the course of
EAE, leukocytes often accumulate in the perivascular space
inbetween these two BMs. Integrins a 2, a 4, b1, and aXb2 are
involved in T cell extravasation during EAE (Bauer et al., 2009;
Bullard et al., 2007; Tsunoda et al., 2007). Integrins a4 and
aXb2 are implicated in interactions with endothelial cells, while
integrin a2 is probably required for interaction with ECM com-
ponents. Combined ablation of MMP-2 and MMP-9 leads to
defects in leukocyte penetration of the parenchymal BM, but
not the endothelial BM (Agrawal et al., 2006). MMP-2 and
MMP-9 are also involved in proteolytic degradation of the
epidermal BM by LCs (Ratzinger et al., 2002). Integrin a6 is
also required for LCs to traverse the BM; this is probably relatedDevelopmental Cell 19, July 20, 2010 ª2010 Elsevier Inc. 13
Figure 1. Varying Mechanisms of Migration in Different
Environments
A generic scheme illustrating similarities between how leukocytes and cancer
cells move through a range of different environments is shown. The size of the
text indicates the relative importance of the following cell functions for the
different types of cell migration: cell-cell adhesion, cell-matrix adhesion, actin
protrusion, cortical contraction, and protease function.
(A) Cells crossing the parenchymal BM are highly dependent on integrins to
directly engage BM components. MMPs then degrade BM components
before actin polymerization moves the cell through the space created.
(B) Cells migrating through sparse interstitium use actin protrusion to extend
the cell forward and cortical contraction to move the cell body behind and
enable squeezing through gaps. Hydrostatic pressure generated by squeezing
can also help to propel the cell forward. If large gaps are presented, there is
less dependence on actomyosin contractility for migration.
(C) Cells migrating through dense interstitium require MMP function to degrade
the matrix when the gaps are too small for cells to squeeze through.
(D) Cells entering lymphatic vessel exploit the gaps between the button-like
endothelial cell junctions to move into the vessels.
(E) Paracellular transendothelial migration requires transient disruption of
junctional adhesion complexes as the invading cells move between adjacent
endothelial cells. Cell-cell interactions between the transmigrating cell and
endothelial cells are important.
(F) Cells crossing the BM at permissive sites have a low dependence on
MMPs.
(G) Cells degrading the endothelial BM are dependent on integrins to directly
engage BM components. MMPs then degrade BM components.
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what surprisingly, gene ablation of several major serine prote-
ases and MMPs in neutrophils still permits normal trafficking of
neutrophils in vivo (Balbin et al., 2003; Betsuyaku et al., 1999;14 Developmental Cell 19, July 20, 2010 ª2010 Elsevier Inc.Levesque et al., 2004; Pham, 2006). This implies either extensive
redundancy between proteases or protease-independent mech-
anisms for crossing BMs (discussed in more detail in ‘‘Exiting the
Vasculature,’’ below). Pharmacological inhibition of actomyosin
contractility driven by Rho-kinase (ROCK) reduces leukocyte
accumulation in EAE (Sun et al., 2006). However, it has not
been determined if this was specifically due to defects in transit
of cells through the BM.
The difficulties in directly studying the transit of cells across
parenchymal BMs in mouse models have led to the use of other
systems. Reconstituted BM matrices (such as Matrigel) can be
generated but the cross-linking and structure of these matrices
differs from native BMs. The use of ex vivo preparation of BM
can provide a more realistic model system. These models have
suggested that only the membrane-tethered proteases, MMP-
14, -15, and -16 are important for cancer cells to cross BMs
(Hotary et al., 2006) (MMP-14, -15, and -16 are also known as
MT1-MMP, MT2-MMP, and MT3-MMP, respectively). An ele-
gant and tractable in vivo system for studying transit through
an epithelial BM is anchor cell migration in the Caenorhabditis
elegans (Sherwood and Sternberg, 2003). This work suggests
that integrin signaling in the anchor cell promotes the association
of plasma membrane components including F-actin, Phosphati-
dylinositol 4,5-bisphosphate (PIP2), UNC-34 (Ena/VASP), and
CED-10 (Rac)(Hagedorn et al., 2009; Ziel et al., 2009). The
anchor cell then extends invasive protrusions into the BM (Sher-
wood et al., 2005). Interestingly, mammalian homologs of UNC-
34 (Mena) and CED-10 (Rac) are implicated in invasive behavior
of cancer cells (Philippar et al., 2008; Sahai and Marshall, 2002a).
Localized Proteolysis
Recent work in invasion has focused on the subcellular localiza-
tion of proteases and their proteolytic activity. Myeloid cells have
focalized areas of proteolysis on their ventral surface termed
podosomes. Podosomes have a ring-like organization with regu-
lators of actin polymerization located centrally and cell adhesion
molecules located more peripherally (Linder and Aepfelbacher,
2003). This organization is very similar to structures found in
some invasive cancer cells, termed invadopodia (Figure 2) (Lin-
der, 2009; Linder and Kopp, 2005). Even more strikingly, there
is considerable overlap in the molecular machinery required for
the formation of podosomes and invadopodia. Both invadopodia
and podosomes can be induced by receptor tyrosine kinase
(RTK) signaling (for example, EGFR signaling in cancer cells
and CSF-1R signaling in myeloid cells) (Jones et al., 2002;
Wheeler et al., 2006a; Yamaguchi et al., 2005a). Src-family
kinases are activated downstream of RTKs. In addition, RTK
signaling activates the small G protein Cdc42 and subsequently
WASp family proteins (Yamaguchi et al., 2005a). Specifically,
WASp is activated in myeloid cells, whereas N-Wasp is activated
in cancer cells. Src-family kinases then act together with WASp
and N-Wasp to promote actin polymerization by the Arp2/3
complex (Bharti et al., 2007; Oikawa et al., 2008). This helps
to generate the actin-rich core of podosomes/invadopodia.
Adhesion complex proteins are then recruited before localized
delivery of vesicles containing proteases such as MMP-14
in cancer cells (Artym et al., 2006). A key feature of MMP-14 is
its membrane localization, which restricts proteolysis to
membrane-proximal locations. However, it is likely that leuko-
cytes use a somewhat different spectrum of proteases, as not
Figure 2. Structure of Podosomes/Invadopodia
Certain leukocyte lineages and cancer cells form localized matrix degrading
structures called podosomes and invadopodia, respectively. Podosomes
and invadopodia consist of a core of F-actin (pink chevron) and actin-associ-
ated proteins including WASp/N-WASP (yellow), cortactin, and Arp2/3 (dark
green). This core is surrounded by adhesion molecules (integrins, dark blue)
and their adaptor proteins (light blue) including talin, paxillin, and Src-family
kinases (dark pink).
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many similarities between podosomes and invadopodia exist,
they are not identical. Podosomes are typically smaller, more
transient, and frequently organized into ‘‘rosette’’-like rings
(reviewed in Linder, 2009). The distinction between the central
actin-rich zone and marginal adhesion zone is often much less
pronounced in invadopodia. Effort is now being concentrated
on imaging the existence and role of these structures in vivo.
Crossing the Basement Membrane without Proteases?
During the routine trafficking of immune cells, the overall integrity
of the BM is not compromised. This might indicate that leuko-
cytes can cross the BM without proteolysis. Recent data has
also suggested that cancer cells may be able to cross BMs in
the absence of histologically detectable degradation of the BM
(Husemann et al., 2008). The adaptable morphology of leuko-
cytes enables them to squeeze through gaps of 2 mm in size.
However, the largest pores in the BM are 50 nm. Therefore,
BM remodeling is needed for cells to traverse from one side to
the other. The ability of both leukocytes and epithelial cells to
physically move BM components out of the way may comple-
ment or substitute for proteolysis. Epithelial cells can use acto-
myosin force to displace BM components (Rabinovitz et al.,
2001). Actomyosin force is particularly critical for cancer cells
to move through reconstituted BM matrices in the absence of
proteases (Sahai and Marshall, 2003). Additionally, some leuko-
cytes appear to induce endothelial cells to displace the under-
lying BM (Rabodzey et al., 2008). This displacement may be
temporary and rapidly reversed. The cross-linked nature of the
parenchymal BM would counteract the ability of cells to move
the BM. However, leukocytes, and possibly cancer cells, maypreferentially cross parenchymal BMs at sites of reduced
cross-linking. The idea of preferred crossing points has recently
been demonstrated for endothelial BMs (see section on ‘‘Exiting
the Vasculature,’’ below).
Chronic versus Acute Loss of Parenchymal Basement
Membrane Integrity
Pronounced defects in the epithelial BM is a defining character-
istic of the transition from benign to malignant disease (Engbring
and Kleinman, 2003). In addition to proteolytic degradation of the
BM, chronic defects in the synthesis and assembly of the BM can
facilitate invasive behavior. Normally epithelial cells contribute to
the formation of the BM through the synthesis and polarized
secretion of BM components. Perturbations in these processes
in transformed cells could account for the loss of BM observed
in cancers. Aberrant epigenetic silencing of collagen IV and lam-
inin 332 (laminin 5) encoding genes is observed in prostate
cancers and correlates with poor prognosis (Ikeda et al., 2006;
Sathyanarayana et al., 2003). Loss of collagen VII within the
BM that connects the epidermis to the dermis promotes invasive
behavior of squamous cell carcinomas (SCCs) (Martins et al.,
2009). This finding provides an explanation for the aggressive
nature of SCC in epidermolysis bullosa patients carrying muta-
tions in the human collagen VII gene (Fine et al., 2009).
The disruption of epithelial polarity can also result in a defective
BM. The polarity protein Par-1 is required for the correct
assembly of laminin on the basal surface of epithelial cells
(Masuda-Hirata et al., 2009). In addition, reduced expression of
the two polarity genes, Dlg and Scribble, is linked to aberrant
tissue and BM organization and the malignant progression of
colon and breast cancer (Gardiol et al., 2006; Zhan et al.,
2008). Erroneous accumulation of the BM components on both
sides of the Drosophila follicular epithelium leads to loss of
epithelial integrity and invasion (Denef et al., 2008). Therefore,
loss of BM integrity may be attributable to chronic factors in
addition to the acute remodeling linked to cell movement.
Intravital imaging of tumors has revealed that amoeboid
cancer cells are relatively rare even in areas with extensively dis-
rupted BMs. These data suggest that loss of BM integrity may
not be a consequence of excessive cancer cell migration but
may result from some of the chronic mechanisms outlined
above. These same studies also revealed a correlation between
the high densities of tumor-associated macrophages and motile
cancer cells (Wyckoff et al., 2004, 2007). Although routine leuko-
cyte trafficking does not lead to loss of BM integrity, excessive
transepithelial migration of leukocytes can lead to tissue
damage. Neutrophil trafficking to inflamed mucosal epithelial
tissue ultimately leads to disruption of the barrier function (Huber
and Weiss, 1989). Several studies have suggested that aberrant
leukocyte function can promote cancer cell invasion. In partic-
ular various myeloid lineages have been implicated, including
macrophages, Gr1+CD11b+ cells, and CD34+ cells (Kitamura
et al., 2007; Yang et al., 2008). These immature myeloid cells infil-
trate into the invasive front of tumor tissues and provide a source
of both MMPs and Cathepsin proteases (DeNardo et al., 2009;
Joyce et al., 2004; Kitamura et al., 2007; Ouyang et al., 2008).
Thus, BM degradation need not be inherently coupled to cancer
cell motility, but may be merely creating an environment that is
permissive for cancer invasion. Analysis focusing solely on
cancer cells, therefore, will not provide the whole story.Developmental Cell 19, July 20, 2010 ª2010 Elsevier Inc. 15
Figure 3. Amoeboid Cell Movement through Interstitial Tissue
Leukocytes and some invasive tumor cells move through the interstitial tissue
using an ‘‘amoeboid’’ mode of motility. Amoeboid movement can be guided by
chemokines (yellow) that locally promote Arp2/3 (blue) dependent actin poly-
merization (pink). This sets the direction of cell movement. Contraction of the
cortical actomyosin network (pink and black) couples the movement of the
protrusion to the rest of the cell body. Cortical contraction can enable
squeezing of the cell through small gaps without the need for matrix proteol-
ysis. In addition, hydrostatic pressure generated by cortical contraction may
help to push the leading protrusion forward. The exact contribution of Arp2/
3-dependent actin polymerization and actomyosin contraction to cell propul-
sion can vary depending on cell type and environmental conditions.
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Epithelial tissues are typically supported by underlying interstitial
tissue. For example, the epidermis is supported by the dermis.
Interstitial tissue is a heterogeneous network of fibrous scaffolds
of which collagen I is the most abundant. The composition and
density of the meshwork varies between tissues. Experimental
analysis has demonstrated that the exact nature and density of
the interstitial matrix has a significant impact on cell migration
(Sabeh et al., 2009). If gaps between fibers are large, cells may
be able to simply move between and around fibers without the
need for proteolytic degradation (Figure 1B). However, if the
fibrous network is dense, proteolysis may be required (Fig-
ure 1C). Accurate determination of the geometry of interstitial
tissue is surprisingly difficult. Electron microscopy methods are
prone to artifacts arising during tissue preparation, such as
extraction or shrinkage of some matrix components. In situ
optical techniques are generally limited to visualizing two or three
matrix components at any one time. This means that a lack of
a specific signal cannot be simply interpreted as a lack of matrix.
Furthermore, three-dimensional imaging of tissues struggles to
achieve a resolution below 1 mm in the z-axis.
Leukocytes can move through interstitial tissue at high
speeds, frequently >10 mm/min (Friedl and Weigelin, 2008). Their
movement is characterized by a rapidly changing cell shape,
which enables them to squeeze between fibers in the matrix.
This type of motility is termed amoeboid. Striking parallels
between leukocyte and cancer cell movement through the
interstitium are becoming apparent. Intravital imaging reveals
that some cancer cells can also move at high speeds (up to
10 mm/min) with similar amoeboid morphologies to leukocytes
(Giampieri et al., 2009; Wyckoff et al., 2000). However, many
cancer cells are not restricted to amoeboid motility (see section
on ‘‘Plasticity: Different Strategies for Different Barriers’’).
Regulation of Actin Dynamics
Like almost all forms of cell motility, amoeboid movement
through the interstitial tissue is driven by coordinated actin poly-
merization and actomyosin contraction (Figure 3). The molecular
mechanism underlying directed leukocyte migration has recently
been reviewed in detail (Friedl and Weigelin, 2008). In brief, a
variety of promigratory signals either activate RTKs or G-protein-
coupled receptors (GPCRs). Both classes of receptor promote
PI-3 kinase and Rac signaling. The guanine nucleotide exchange
factors (GEFs) Vav1, 2, and 3 mediate Rac activation down-
stream of RTKs, while the Rac GEFs P-Rex and Tiam-1 couples
GPCRs to Rac (Hill and Welch, 2006; Hornstein et al., 2004;
Gerard et al., 2009). Feedback mechanisms involving PI-3 kinase
allow continued directional migration (Rickert et al., 2000). Active
Rac then promotes Arp2/3-mediated actin polymerization that
pushes the plasma membrane outward (Figure 3). Analysis of
Rac1- and Rac2-deficient macrophages suggests that other
parallel pathways can also drive actin polymerization (Wheeler
et al., 2006b). One such possible parallel pathway involves the
actin regulator Dia1, which is required for effective T cell migra-
tion (Eisenmann et al., 2007). After actin-driven extension of the
plasma membrane, RhoA-driven actomyosin contraction
ensures that the rest of the cell body follows behind (Figure 3).
The properties of the actomyosin cortex that underlies the
plasma membrane are critical for amoeboid migration. Contrac-
tility of the cortical actin network is important to deform and16 Developmental Cell 19, July 20, 2010 ª2010 Elsevier Inc.propel the nucleus of dendritic cells (DCs), B-lymphocytes, and
granulocytes through small gaps that would otherwise physically
constrain the cell (Lammermann et al., 2008). In addition to the
cortical actin, there is a network of intermediate filament proteins
that forms a cellular corset around the cell body of migrating
leukocytes (Brown et al., 2001; Tooley et al., 2009).
Many of the same molecular players are implicated in the move-
ment of cancer cells through interstitial-type matrices. Rac-medi-
ated regulation of the Arp2/3 complex can promote the formation
of actin-rich protrusions that drive cell motility (Olson and Sahai,
2009). RhoA-ROCK signaling regulates the actomyosin cortex
and couples movement of the cell body to the front of the cell
(Sahai and Marshall, 2003; Wyckoff et al., 2006). These findings
are not particularly surprising, as these molecules underpin
almost all modes of cell migration. However, mechanistic analysis
has revealed some unexpected similarities in the role of integrins
and proteases in leukocyte and cancer cell movement.
Limited Dependence on Integrins and Proteases
Dendritic cells, T cells, B cells, and granulocytes can migrate
from the interstitium to the lymph nodes independently of integ-
rins (Friedl and Brocker, 2000; Lammermann et al., 2008). This
contrasts dramatically with the need for integrins in movement
Developmental Cell
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movement of melanoma cells through collagen matrices is not
dependent on integrin b1 (Hegerfeldt et al., 2002), which is
required for adhesion to collagen. A further surprising parallel
is the low limited dependence on protease function. A very broad
range of MMPs, and serine and cysteine proteases can be
inhibited without preventing cancer cells from moving through
either collagen I networks or deformable laminin-rich matrices
(Carragher et al., 2006; Lammermann et al., 2008; Sahai and
Marshall, 2003; Wolf et al., 2003). The high speed of amoeboid
motility also suggests that significant proteolysis is unlikely to
be occurring as leukocytes are moving through interstitial tissue.
It is likely that this rapid form of movement utilizes pre-existing
gaps in the matrix that can be considered ‘‘permissive’’ for
migration. At very high concentrations of collagen I, cancer cell
movement becomes dependent on MMP-14 (Sabeh et al.,
2009; Wolf et al., 2007). However, intravital imaging of experi-
mental tumors in mice treated with a broad spectrum MMP inhib-
itor did not affect the amoeboid movement of cancer cells
(Wyckoff et al., 2006). This suggests that the interstitial matrix
surrounding tumors has sufficiently large gaps that proteolysis
of the ECM is not acutely required for cancer cells to move.
Also, altered regulation of the cortical cytoskeleton in cancer
cells may facilitate the squeezing of cancer cells through gaps.
Overexpression of RhoA and RhoC in numerous cancers
promotes cortical actomyosin contractility (Sahai and Marshall,
2002b; Sahai and Marshall, 2003), whereas altered regulation
of septins may further aid the deformation of cells required for
movement through narrow gaps (Russell and Hall, 2005; Tooley
et al., 2009).
When considering the parallels between leukocyte and cancer
cell migration through the interstitium it should be remembered
that cancer cells can move as ‘‘amoeboid’’ single cells, with an
elongated ‘‘mesenchymal’’ morphology, or even in cohorts.
The limited protease and integrin dependence only applies to
the amoeboid type of motility (for reviews of other cancer cell
migration strategies, see Friedl and Gilmour, 2009; Kalluri and
Weinberg, 2009). It is likely that all these forms of motility can
contribute to metastasis. Nonetheless, the importance of amoe-
boid motility is underscored by several studies that correlate this
type of motility with blood-borne metastasis (Philippar et al.,
2008; Sahai et al., 2005; Wang et al., 2004b; Xue et al., 2006).
Guidance Cues
Effective immunity requires that leukocytes move in a directed
manner in response to extracellular cues. The major guidance
mechanisms for leukocytes are secreted polypeptides called
chemokines. These can be associated with the surface of
some cells, matrix components, or be freely diffusible. It is
thought that gradients of these factors can guide the movement
of leukocytes within certain tissues. For example, CXCL12 (also
called SDF-1a) production by dermal fibroblasts following
inflammatory cues helps to guide LCs that have upregulated
the CXCL12 receptor CXCR4 into the dermis (Ouwehand et al.,
2008). Once in the dermis, LCs start upregulating CCR7, conse-
quently inducing their migration toward lymphatic vessels that
produce the CCR7 ligand CCL21 (Ohl et al., 2004). Similarly,
CCR7 expression increases as DCs mature in the lungs, and
CCR7 signaling guides mature DCs to bronchial-associated
lymphoid tissue (Grayson et al., 2007). Chemokines act bybinding to chemokine receptors (GPCRs) and promoting actin
polymerization at the front of the cell. This then determines the
overall direction of movement (see above). Positive feedback
at the front of the cell and negative feedback at the sides and
rear enables leukocytes to respond efficiently to shallow gradi-
ents (for more detailed reviews, see Bagorda and Parent,
2008; Charest and Firtel, 2006).
A range of extracellular cues can cause cancer cells to move in
a directed fashion. These include growth factors that signals
through RTKs and chemokines that signal through GPCRs. Che-
mokine receptors are not highly expressed in normal epithelial
cells; however, they are highly expressed in several solid tumors
and can promote metastasis (Zlotnik, 2006). CXCR4, CCR7,
CCR5, and several other receptors are upregulated in many
cancers and are positively correlated with metastasis (Balkwill,
2004; Buonamici et al., 2009; Geminder et al., 2001; Kawada
et al., 2007; Kawada et al., 2004; Muller et al., 2001; Pan et al.,
2006; Phillips et al., 2003; Scotton et al., 2002; Shields et al.,
2007; Taichman et al., 2002; Uchida et al., 2004). The importance
of chemokine receptors in guiding cancer cells to the lymphatic
system was shown by ectopic expression of CCR7 in B16 mela-
nomas, which resulted in greatly enhanced cancer cell spread to
draining lymph nodes. Furthermore, this process was dependent
on CCL21 (Wiley et al., 2001). Thus, cancer cells can acquire the
expression and function of receptors that normally guide leuko-
cytes to lymphatic vasculature. However, cancer cells are rarely
as effective as leukocytes at responding to chemokine gradients
(Zicha and Dunn, 1995). One possible explanation may be that
mutations altering PI-3 kinase signaling in cancer cells interfere
with the feedback mechanisms that refine leukocyte chemo-
tactic responses (Vogt et al., 2009).
Other cues besides chemokines can also determine the direc-
tion of cell migration. The movement of hematopoietic stem and
progenitor cells from tissues into draining lymphatic vessels is
dependent on S1P1 receptor signaling (Massberg et al., 2007).
S1P is abundant in lymph fluid, whereas its interstitial concentra-
tion is very low, thereby promoting interstitial migration toward
the lymphatics. In the context of tumor invasion, S1P/S1P1
signaling stimulates cell migration and invasion of several tumor
cell lines in vitro (Fisher et al., 2006; Li et al., 2009). Certain cyto-
kines can also act as chemotactic cues for both leukocytes and
cancer cells. For example, CSF-1/CSF-1R signaling can guide
the movement of macrophages, and the upregulation of
CSF-1R in human breast cancer is associated with invasion
(Sapi, 2004; Webb et al., 1996). Cancer cells can also use a range
of other RTKs such as EGFR and HGF to guide their movement
(Klominek et al., 1998; Segall et al., 1996). Thus, similarities
between the movement of leukocytes in the interstitium and
amoeboid cancer cells may be partly due to the use of common
ligands and receptors (see section on ‘‘Plasticity: Different Strat-
egies at Different Stages’’).
Entry into the Vasculature
Peripheral leukocytes enter the blood via the draining of lymph
through the thoracic duct. This process is essentially passive,
and the rate-limiting event is most likely the initial entry of cells
into the lymphatic vasculature. In contrast, there is much
evidence to suggest that cancer cells can directly enter the blood
without first passing through the lymphatic system.Developmental Cell 19, July 20, 2010 ª2010 Elsevier Inc. 17
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As described above, chemokine gradients can guide both leuko-
cytes and cancer cells toward lymphatic vessels. The initial
peripheral lymphatic walls have an unusual organization. Instead
of continuous cell-cell junctions, lymphatic endothelial cells have
a punctuated arrangement of junctions (Baluk et al., 2007). This
organization has been described as ‘‘button-like’’ (Figure 1D).
The spacing of junctions is 3 mm (McDonald, 1994) which is
roughly compatible with the limits of leukocyte and cancer cell
squeezing (Wolf et al., 2007). Furthermore, BM components at
these junctions are relatively sparsely distributed. These features
mean that entry into these vessels may have a low dependence
on both proteases and integrins (Lammermann et al., 2008). Ex
vivo imaging of entry into lymphatic vessels revealed that DCs
use ‘‘pre-formed’’ portals in the lymphatic endothelium and do
not require pericellular proteolysis (Pflicke and Sixt, 2009).
Leukocytes are thought to interact directly with the lymphatic
endothelium. Neutralizing antibodies to ICAM-1 and VCAM-1
block DC adhesion and transmigration over lymphatics in vivo,
and ICAM-1-deficient mice have impaired LC migration to LNs
(Xu et al., 2001). However, integrins are not thought to be the
binding partner of ICAM-1 or VCAM-1 in this setting, because
DCs, granulocytes, and B cells lacking all functional integrins
can still migrate from the periphery into lymphatic vessels (Lam-
mermann et al., 2008).
Entry into the Blood
Direct entry into the blood is likely to be more physically chal-
lenging than entry into initial peripheral lymphatic vessels. Entry
into the blood requires cells to cross two structures: the endo-
thelial cell layers that line the vessel and the BM that supports
the endothelial cells. Mural cells, such as pericytes, stabilize
the endothelial BM and provide an additional complication. Entry
of leukocytes directly into the blood is not well understood and
may be infrequent in peripheral tissues. Imaging studies in the
zebrafish have revealed that neutrophils can traffic back into
the blood from sites of wound healing (Mathias et al., 2006).
Furthermore, the blood vessel wall was traversed at similar
points by both neutrophils exiting the blood and those returning
from the wound. It is possible that certain crossing points are
favored because they have a weaker or partially degraded endo-
thelial BM. In tumor models, there is a close spatial relationship
between sites of monocyte/macrophage exit from the blood and
entry of cancer cells into the blood. The sites used for monocyte
extravasation may additionally facilitate cancer intravasation.
Moreover, macrophages produce EGF, a chemotactic ligand
for many cancer cells that may guide them toward perivascular
macrophages (Wyckoff et al., 2004).
The vascular network in tumors is typically disorganized. The
vascular BM in tumors has a looser association with both endo-
thelial cells and pericytes, irregular thickness, focal holes, and
broad extensions into the tumor stroma (Baluk et al., 2003; Mor-
ikawa et al., 2002). Although holes in the BM are rarely observed,
their dimension (2.5 mm) could allow tumor cells to enter/exit
the vessels without major physical disruption of the BM (Baluk
et al., 2003). Leaky blood vessels thus serve as the perfect
escape route of tumor cells.
During the process of intravasation, cells go from an environ-
ment with very low shear stress to one with high shear stress.
The high shear forces applied to cells as a result of blood flow18 Developmental Cell 19, July 20, 2010 ª2010 Elsevier Inc.have the potential to damage them. Leukocytes have a cortical
cytoskeleton that can accommodate extensive deformation,
enabling them to cope with cell shape changes caused by shear
stress in the blood vessel (Brown et al., 2001; Redenbach et al.,
1997). In contrast, the cytoskeleton of a typical epithelial cell and
many cancer cells is not adapted to withstand these stresses.
Cells with low metastatic potential that do not move in an amoe-
boid manner are observed to fragment during the process of
intravasation (Wyckoff et al., 2000). This has been correlated
with switching in the expression of intermediate filament pro-
teins, including keratin 13 and 19, and increased expression of
regulators of cortical actomyosin contraction, including RhoA
and ROCK1 (Wang et al., 2002). A direct demonstration of the
relevance of these changes to a cell’s ability to withstanding
shear stress is still lacking. Nonetheless, manipulations that
increase Rho-ROCK-driven cortical actomyosin contractility
promote the extension of bleb-like protrusions by cancer cells
into blood vessels and enhance their short-term survival fol-
lowing injection into the blood (Pinner and Sahai, 2008; Sanz-
Moreno et al., 2008; Stoletov et al., 2007).
Exiting the Vasculature
Transendothelial extravasation—the exit of cells from the circu-
lation—has been more intensively studied than intravasation.
In particular, the trafficking of leukocytes to sites of infection
and the entry of cancer cells into the lungs has been analyzed.
The molecular mechanisms underlying transmigration of leuko-
cytes across the endothelium can be divided into a stepwise
cascade: (1) initial capture, (2) rolling along the vessel wall (medi-
ated by selectins), (3) arrest, adhesion strengthening and
spreading mediated by ICAM-1 and VCAM-1, (4) intravascular
crawling, (5) endothelial transmigration (diapedesis), and (6)
crossing the endothelial BM (Ley et al., 2007). Following selec-
tin-mediated rolling, integrin activation is a critical requirement
for the arrest of leukocytes on vessel walls and their subsequent
transmigration. Mutations in either integrin b2 or the intracellular
regulator of integrin function, Kindlin-3, lead to immunological
disease associated with defective adhesion to vessel walls
(Kishimoto et al., 1987; Malinin et al., 2009; Moser et al., 2009;
Svensson et al., 2009). In contrast, the mechanisms of cancer
cell arrest are less stereotypic. In many cases, the arrest of
cancer cells is simply the result of their large size relative to the
capillary vessels (Morris et al., 1993). Association with platelets
can further enhance the arrest of cancer cells (Gasic, 1984).
Specific receptor-ligand binding events may also occur (Witz,
2006). The subsequent events of diapedesis and crossing the
endothelial BM are often considered as one process. However,
we will discuss the two processes separately.
Traversing Endothelial Cells
The penetration of the vascular wall takes place through two
mechanistically divergent routes: the paracellular route and the
transcellular route. Paracellular diapedesis (moving between
cells) is the most common form of transmigration (Figure 1E).
Leukocytes traverse the endothelium through cell-cell junctions.
This involves the engagement of various endothelial adhesion
molecules (including ICAM-1, ICAM-2, VCAM-1, PECAM-1,
JAMs, CD99, ESAM, and VE-Cadherin) by leukocytes integrins
(predominantly aLß2, aMß2, and a4b1) (Aurrand-Lions et al.,
2002, 2005; Greenwood et al., 1995; Luscinskas et al., 1994;
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et al., 2005). The firm adhesion of T cells to the endothelium is
associated with aLb2 clustering in T cells. This can lead to the
formation of actin-containing filopodia that facilitate transendo-
thelial migration (TEM) (Shulman et al., 2009). The clustering of
aLb2 can also induce clustering of endothelial adhesion mole-
cules, like ICAM-1 and VCAM-1, leading to intracellular signaling
pathways that direct the rearrangement of the cytoskeleton and
the formation of a docking structure that can anchor the leuko-
cyte (Barreiro et al., 2002).
Much less is known about the molecular mechanisms under-
lying transcellular migration (Figure 1F). Cytokine-stimulated T
lymphocytes and basophils insert dynamically active podo-
somes (see above) into the apical surface of endothelial cells in
order to probe for sites permissive to transcellular pore formation
(Carman et al., 2007). This palpation by the leukocytes could
serve to sense areas of low endothelial resistance. Once this
lenient area is identified, the podosomes are able to progres-
sively extend into ‘‘invasive podosomes,’’ ultimately resulting in
the development of a transcellular pore. In lymphocytes, the
formation of podosomes is dependent on both Src and WASp
activities. These Src-dependent phosphotyrosine protein-con-
taining invasive structures are distinct from the Cdc42-depen-
dent filopodia that have been reported in other studies (Shulman
et al., 2009). Interestingly, these invasive podosomes were only
a requirement for transcellular and not paracellular transmigra-
tion (Carman et al., 2007).
Endothelial cells also undergo pronounced changes during
TEM. Microvilli-like endothelial membrane protrusions embrace
the leukocyte during transcellular TEM (Barreiro et al., 2002;
Carman et al., 2003). This apical ‘‘transmigratory cup’’ structure
requires localized actin polymerization (Barreiro et al., 2002;
Carman et al., 2003), an intact microtubule cytoskeleton (Car-
man et al., 2003), and intermediate filament networks (Nieminen
et al., 2006) in endothelial cells. However, the transmigratory cup
is not universally observed (Mamdouh et al., 2009; Shulman
et al., 2009). The development of the transcellular pore within
the endothelial cells has been reported to involve membrane
recycling compartments, SNARE-driven membrane fusion
events, and caveolin (Carman et al., 2007; Mamdouh et al.,
2009; Millan et al., 2006). Downregulation of Caveolin-1 in endo-
thelial cells favors paracellular migration (Marmon et al., 2009;
Millan et al., 2006).
There is extensive literature documenting the molecular
requirements for cancer cells to efficiently colonize lung tissue,
a process that begins with exit from the vasculature (Chambers
et al., 2002). However, the majority of these studies quantify lung
colonization many days after the injection of cells into the blood.
Thus, specific information regarding the role of key molecules in
crossing the endothelial cell layer or endothelial BM is often lack-
ing. Nonetheless, certain principles can be deduced from these
studies and the smaller number of more detailed studies. Cancer
cells do not express high levels of the leukocyte integrins that
engage the endothelial junctional adhesion molecules. This
may partly explain why cancer cell extravasation is an inefficient
process. However, the more widely expressed integrin aVb3,
which can bind PECAM-1, has been functionally implicated in
numerous studies of cancer cell extravasation (Bauer et al.,
2007; Kikkawa et al., 2002). Integrin aVb3may well have a dualrole in promoting cell exit from the vasculature as it can also
bind a range of other matrix ligands (Humphries et al., 2006).
Activation of the VCAM-1 binding integrin a4b1in melanoma cells
can also promote extravasation (Klemke et al., 2007; Langley
et al., 2001; Liang and Dong, 2008). Cancer cells are believed
to utilize paracellular routes for TEM, but some recent work
has suggested that transcellular routes may also be used (Trem-
blay et al., 2008). It is possible that in the same way leukocytes
use podosomes during transcellular TEM, tumor cells use inva-
dopodia during transcellular TEM.
Local inflammatory signals can promote leukocyte extravasa-
tion. Paracrine signals produced by inflamed tissue, such as
TNFa, trigger the weakening of endothelial cell junctions and
facilitate the extravasation of leukocytes into areas of inflamma-
tion. Cancer cells can also use a similar paracrine strategy to
weaken endothelial junctions and enhance paracellular TEM.
Angiopoietin-like 4 expression by breast cancer cells can lead
to the disruption of endothelial cell-cell junctions and promote
the extravasation of cancer cells into the lungs (Padua et al.,
2008). In other cases, cancer cells induce retraction of endothe-
lial cells by releasing the lipid 12(S) hydroxyeicosatetraenoic acid
(Honn et al., 1994a; Honn et al., 1994b). Vascular endothelial
growth factor (VEGF) and the chemokine stromal-derived growth
factor 1 (Sdf-1)/CXCL12 have also been implicated in compro-
mised endothelial integrity and retraction of the endothelial cells
during cancer cell transmigration (Lee et al., 2004). In addition,
some tumor cells release reactive oxygen species (ROS), which
can irreversibly damage and cause the retraction of the endothe-
lium (Orr et al., 2000).
In some cases, the endothelial cell layer may not need to be
crossed. Cancer cells have been observed binding directly to
exposed laminin 332 in endothelial BMs via integrin a3b1
(Figure 1G). Surprisingly, areas of exposed BM were also
observed in the lungs of control mice without circulating tumor
cells (Wang et al., 2004a). Expression of a6b1-integrin by mela-
noma cells can enhance their adhesion to both the endothelium
and the BM underneath. This may account for the role of integrin
a6b1 in melanoma metastasis to the lung and liver (Hangan et al.,
1997; Ruiz et al., 1993).
Crossing the Endothelial BM
Once cells have crossed the endothelial cell layer, they then
penetrate the endothelial BM (Figure 1H). Similar to crossing
epithelial BMs, integrins and proteases have been extensively
implicated in this process. Traversing of endothelial BMs by
neutrophils involves integrin a6 and neutrophil elastase (Wang
et al., 2005). MMPs are also involved in BM crossing by leuko-
cytes. MMP-2, MMP-9, and MMP-14 are involved in the crossing
of endothelial BMs by T cells (Esparza et al., 2004; Savinov et al.,
2005). MMP-2 and MMP-9 have further been implicated in
neutrophil transit through BMs (Reichel et al., 2008). Interest-
ingly, MMP-14 is not expressed in neutrophils (Kang et al.,
2001), perhaps indicating that these cells use a distinct mecha-
nism from T cells. Although various strategies aimed at blocking
these proteases reduce leukocyte transit through the BM, none
completely prevented it. This could simply be a result of experi-
mental limitations or it could indicate that there are protease-
independent mechanisms involved in crossing the BMs. In
support of this latter idea, emigrating neutrophils and monocytes
have been shown to preferentially exit the venular wall atDevelopmental Cell 19, July 20, 2010 ª2010 Elsevier Inc. 19
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components, including laminin 511 (laminin 10), collagen IV,
and nidogen-2 (Voisin et al., 2009; Wang et al., 2006). The impor-
tance of low expression sites of laminin a5 has also been
observed during extravasation of CD4+ T cells into the brain
(Sixt et al., 2001; Wu et al., 2009). These permissive sites are
closely associated with gaps between pericytes (Wang et al.,
2006). The transmigration of neutrophils is directly associated
with transient remodeling of the entry sites (Voisin et al., 2009).
The molecular mechanism underlying BM remodeling by neutro-
phils is still elusive. Neutrophil elastase has been implicated in
BM proteolysis and integrin a6b1 may play a role in moving the
laminin fragments from the BM. Monocytes that do not remodel
the BM exhibit greater squeezing as they cross the BM. It
remains to be determined whether cancer cells also use similar
sites of ‘‘permissive’’ endothelial BM to move into secondary
tissues. The limited protease dependence of some melanoma
cells for exiting the lung vasculature provides some support for
this idea (Wylie et al., 1999). Although many studies have demon-
strated roles for MMPs in metastasis in end-point assays that
take many weeks, there is very little in vivo data specifically
determining their role in extravasation (Deryugina and Quigley,
2006). There is also accumulating evidence that bone marrow
derived cells arrive at metastatic sites prior to the cancer cells
and establish a ‘‘premetastatic niche’’ (Kaplan et al., 2005;
Qian et al., 2009). This may involve the generation of favored
sites for BM crossing in addition to expression of the chemokine
CXCL12.
Plasticity: Different Strategies at Different Stages
The molecular mechanisms employed to cross different matrix
barriers are varied. Integrins and proteases are usually neces-
sary for both cancer cells and leukocytes to traverse intact
epithelial BMs but are largely dispensable for movement through
interstitial tissue. This implies that cells are able to switch
between distinct modes of invasive behavior as they move
through the body. Furthermore, this plasticity in behavior may
be required for cells to move through diverse tissues. It is likely
that leukocytes have evolved to be able to switch between types
of motility. However, how do cancer cells of sedentary epithelial
origins acquire the ability to move in the ways described above?
One explanation is that they acquire expression of cell motility
molecules normally restricted to other more motile cell types.
The expression of fibroblast-restricted genes by cancer cells is
well documented (Kalluri and Weinberg, 2009). However, fibro-
blasts are primarily adapted for tissue remodeling, and a simple
conversion to a fibroblast-like state may not be optimal for
crossing diverse tissue boundaries. As discussed above, many
cancer cells also express genes involved in the movement and
guidance of leukocytes and neural cell types, and this may
confer a wider variety of possible cell behaviors on the cancer
cell (Huang et al., 2008; Zlotnik, 2006).
The deregulated expression of genes normally restricted to
more motile cell lineages can account for an increase in the
motility of cancer cells. However, it is not sufficient to explain
how cells might switch between modes of invasion. So, how is
this switching accomplished? One possibility is that the
surrounding microenvironment might modulate the mode of
invasive behavior. The ligand binding activity of integrins can20 Developmental Cell 19, July 20, 2010 ª2010 Elsevier Inc.be modulated in response to a range of environmental cues.
Integrin-mediated adhesions can function as mechanosensors.
If integrins are under tension, positive feedback mechanisms
increase adhesion (Bershadsky et al., 2006). On soft matrices,
only low levels of tension can build up before the matrix deforms.
Therefore, the level of signaling from integrins is low and integrin-
mediated adhesions remain immature (Levental et al., 2009;
Paszek et al., 2005). On more rigid matrices, greater amounts
of tension can build, resulting in increased integrin signaling.
Therefore, if a cell is confronted with a rigid matrix barrier, the
integrin function increases. Subsequent downstream signaling
through the Src-family kinases can also lead to increased pro-
tease function (Frame et al., 2002; Mitra and Schlaepfer, 2006).
The result of these feedback mechanisms is that a rigid barrier
can cause a cell to upregulate the functions that are required
to cross it (integrins and proteases). Similar mechanosensing
mechanisms also enable leukocytes to activate integrins under
conditions of shear stress, such as those encountered by cells
in the process of extravasation (Alon and Ley, 2008). Integrin
function can also be modulated by chemokines. In inflamed
tissues, chemokines expressed by endothelial cells activate
Rap1 and promote integrin activation in leukocytes (Alon and
Ley, 2008). This facilitates their subsequent extravasation.
A similar mechanism may also account for the preferential meta-
static seeding of cells to tissues expressing elevated levels of
chemokines.
Studies using three-dimensional culture systems have shown
that cancer cells switch between nonproteolytic and proteolytic
modes of movement depending on the matrix density (Wolf et al.,
2007). Interconversion between protease-independent and
protease-dependent modes of cancer cell migration is associ-
ated with dramatic changes in cell shape. Protease-independent
migration is associated with a RhoA-ROCK-driven rounded
morphology, whereas protease-dependent migration is linked
with an elongated shape (sometimes termed mesenchymal)
(Carragher et al., 2006; Sahai and Marshall, 2003; Sanz-Moreno
et al., 2008). Elongated motility is driven by Nedd9 and DOCK3-
mediated activation of Rac1 and subsequent actin polymeriza-
tion at the front of the cell (Sanz-Moreno et al., 2008). Exactly
how extracellular cues may influence the balance of RhoA and
Rac1 activities is not clear. Inhibition of protease function
promotes a rounded Rho-dependent morphology, suggesting
that protease function promotes Rac activity. This could occur
through the generation of matrix fragments that modulate Rac
activity or through MMP-14-dependent recruitment of the Rac-
activator p130Cas (Bachy et al., 2008; Gonzalo et al., 2010).
Differential engagement of integrins could also account for
changes in the balance of Rho and Rac activity. The fibro-
nectin-binding integrin a5b1 is strongly coupled to RhoA
activation (Dubash et al., 2007), whereas laminin binding integ-
rins are coupled to Rac1 activation (Gu et al., 2001; Mettouchi
et al., 2001).
While these two types of motility are often presented as
discrete and distinct behaviors, it is more accurate to regard
them as two ends of a continuous spectrum. The amoeboid
movement of rat mammary cancer cells in vivo involves a zone
of actin polymerization at the front of the cells and ROCK-depen-
dent regulation of the actomyosin cortex (Wyckoff et al., 2006).
Similarly, the movement of leukocytes through interstitial tissues
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Rho-driven contractility (Friedl and Weigelin, 2008).Concluding Remarks and Future Directions
Leukocytes are perhaps the best-adapted cells at migrating
through the diverse environments in the body. Their effective
migration is due to their ability to modulate their behavior accord-
ing to the type of tissue boundary they encounter. It is now
becoming apparent that cancer cells also use similar tricks to
spread through the body. If confronted with a dense cross-linked
matrix, such as most BMs, high levels of integrin and protease
function are used to remodel the matrix barrier before moving
through. In a less-dense matrix, both leukocytes and cancer
cells can move very rapidly by squeezing through available
gaps without the need for integrins or proteases.
We have learned much about how both leukocytes and cancer
cells move through the body. Nonetheless, there is still much we
do not understand. Although we know many of the key mole-
cules involved in cell migration through tissues, we still do not
know exactly when and how they act in the context of real
tissues. For example, chemokines and their receptors guide
cell movement, but we know little about if and how gradients
of ligand might be established to instruct motility. Is soluble
ligand required? Or are ligands immobilized on the surface of
stromal cells or the ECM? In vitro assays can demonstrate
how a system might work, but not necessarily how it actually
functions in vivo. Hopefully, the next few years will see greater
analysis of cells moving through real tissues. Transgenic tech-
nologies that enable cell-type specific genetic manipulation will
allow testing of the cell intrinsic requirements for molecular path-
ways versus cell-extrinsic roles in generating either instructive or
permissive environments for cells to move through. Improve-
ments in imaging technologies should provide greater insights
into the specific defects associated with molecular perturba-
tions. Fluorescent probes exist to monitor protease function
in vivo and the activity of numerous signaling pathways can be
determined by FRET probes (Aoki et al., 2008; Weissleder
et al., 1999). These tools will enable monitoring of different
molecular activities as cells move through diverse environments.
Together, these methods should shed light on the diversity and
plasticity of cell migration strategies.ACKNOWLEDGMENTS
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